Developer docs
API playgroundTry for free, no card

Search company profiles

BONESUPPORT

Full company profile

uuid0004izu

Namestring
BONESUPPORT
Legal namestring
BONE SUPPORT AB
Websiteurl
bonesupport.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

BONESUPPORT is a Swedish orthobiologics company that develops and commercializes CERAMENT, a proprietary injectable bioceramic bone graft substitute platform, founded in 2000 and headquartered in Lund, Sweden. The company is publicly listed on Nasdaq Stockholm (BONEX) and operates wholly-owned sales subsidiaries across Europe, the United States, and Switzerland, with a distribution partnership covering India. Its products address bone voids and bone infections caused by trauma, infection, disease, or related surgery across use cases including chronic osteomyelitis, fracture-related infection, diabetic foot osteomyelitis, open fractures, periprosthetic joint infection, and benign bone tumors. Hospital customers include Apollo Hospitals, King's College Hospital London, Oxford University Hospital, Manchester University Hospital, Charité Berlin, and HCA Florida Kendall.

The CERAMENT platform is built on a patented biphasic calcium sulphate/hydroxyapatite composition that remodels to host bone in six to twelve months. The product portfolio consists of four SKUs: CERAMENT BONE VOID FILLER (osteoconductive only), CERAMENT G (gentamicin-eluting for broad-spectrum infection coverage), CERAMENT V (vancomycin-eluting for MRSA/MRSE infections), and the CERAMENT Bead Tray accessory for bead delivery. CERAMENT G holds FDA 510(k) clearance as the first and only product indicated to reduce occurrence and recurrence of bone infection in open fractures; CERAMENT V has received FDA Breakthrough Device designation and is currently progressing through the De Novo pathway. Reported clinical outcomes include a 94% infection eradication rate in chronic osteomyelitis (100 patients, 6.05-year average follow-up), 87.5% five-year survival versus 44.9% standard treatment in diabetic foot osteomyelitis, and a 3.7% deep infection rate versus 14.5% standard of care in Gustilo-Anderson IIIB open fractures.

BONESUPPORT generates revenue through direct B2B sales of medical devices to hospitals and orthopaedic surgeons, with field sales teams covering DACH, BeNeLux, UK & Ireland, the Nordics, Iberia, and the United States, supported by KOL-led clinical training programs and a channel partner (Apollo Hospitals) for India. North America represents approximately 75% of total sales, with Europe (EUROW) contributing the balance plus a small initial contribution from India. FY2025 revenue was SEK 1,175 million (up from SEK 899M in 2024 and SEK 591M in 2023), gross margin was 92.6-92.9%, and EBITDA was positive. The company has 101-250 employees and is led by CEO Torbjörn Sköld (effective September 2025) and CFO Håkan Johansson, with Dr. Michael Diefenbeck as Chief Medical Officer. Recent strategic moves include the India launch (May 2026), CMS NTAP approval and proposed improved reimbursement for CERAMENT G in the US, the SOLARIO study readout, and a SEK 100 million share buyback program completed in June 2026.

Short descriptiontext

BONESUPPORT is a Swedish orthobiologics company that develops and commercializes the CERAMENT injectable bioceramic bone graft substitute platform. It serves hospitals and orthopaedic surgeons globally, with North America representing approximately 75% of revenue and a new India entry via Apollo Hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthobiologic bone grafts, injectable bioceramic substitutes, drug-eluting bone void filler, antibiotic bone graft substitute, calcium sulphate hydroxyapatite
Industry2 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthobiologic Bone Graft Substitutes
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales
TypeOne Time License
Description

BONESUPPORT generates revenue primarily through the sale of its CERAMENT bone graft substitute products. Products include CERAMENT BONE VOID FILLER (standard), CERAMENT G (gentamicin-eluting), CERAMENT V (vancomycin-eluting), and CERAMENT Bead Tray. Sales are direct to hospitals and healthcare providers through field sales teams.

bonesupport.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Pricing details1 tier
1No public pricing available - B2B medical device sales through hospital procurement
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing is determined through direct sales engagements with hospitals and healthcare systems. No public price list available.

bonesupport.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CERAMENT
Description

Innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products for bone graft substitutes that remodel to host bone in six to twelve months.

bonesupport.com
Core offering1 text field

BONESUPPORT develops, manufactures, and commercializes the CERAMENT platform of injectable radiopaque osteoconductive bioceramic bone graft substitutes that remodel to host bone in six to twelve months. The product range includes CERAMENT BONE VOID FILLER for bone void filling, CERAMENT G (gentamicin-eluting) and CERAMENT V (vancomycin-eluting) antibiotic-eluting variants for bone infection management, and the CERAMENT Bead Tray accessory for bead preparation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 94% infection eradication rate in chronic osteomyelitis (100 patients, avg 6.05 year follow-up)
+5 more records
Product overview1 text field

BONESUPPORT is a Scandinavian orthobiologics company that has developed CERAMENT®, a proprietary technology platform of radiopaque injectable osteoconductive and drug-eluting bioceramic products. The product portfolio consists of four main offerings: CERAMENT® BONE VOID FILLER (core bone void filler without antibiotic), CERAMENT® G (gentamicin-eluting antibiotic bone graft), CERAMENT® V (vancomycin-eluting antibiotic bone graft), and CERAMENT® Bead Tray (accessory for bead delivery). All products remodel to host bone in six to twelve months. The platform enables treatment of bone defects caused by trauma, infection, disease, or related surgery. The antibiotic-eluting products (G and V) combine infection control with bone regeneration in single-stage surgical approaches.

Product and service4 records
1CERAMENT BONE VOID FILLER
CategoryOrthobiologic Bone Graft Substitute
Description

Radiopaque injectable osteoconductive bioceramic bone graft substitute for filling bone voids and defects, backed by RCT and PROMS data showing bone remodeling outcomes equivalent to autograft. Used for trauma cases at low risk of infection.

2CERAMENT G
CategoryDrug-Eluting Orthobiologic
Description

Antibiotic-eluting bone graft substitute releasing gentamicin locally. Combines infection control with bone regeneration in single-stage treatment. FDA 510(k) cleared for reducing occurrence and recurrence of bone infection in open fractures. Used for high-risk infection cases, diabetic foot complications, chronic osteomyelitis, and fracture-related infections.

3CERAMENT V
CategoryDrug-Eluting Orthobiologic
Description

Antibiotic-eluting bone graft substitute releasing vancomycin locally. Designed primarily for bone infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA) or Methicillin-Resistant Staphylococcus epidermidis (MRSE). FDA submission filed for bone infection indication.

4CERAMENT Bead Tray
CategoryDelivery Accessory
Description

Optional delivery device accessory for preparing and delivering CERAMENT as pre-hardened beads, particularly useful for bone cysts prone to producing large volumes of fluid such as aneurysmal bone cysts.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-07
Description

Apollo Hospitals introduced CERAMENT G in India as the first advanced antibiotic-eluting bone graft substitute for treating diabetic foot complications and complex bone infections. India has over 89 million people living with diabetes. The partnership includes clinical training programs led by Prof. Venu Kavarthapu from King's College Hospital London to deploy the technology across Apollo's multidisciplinary orthopaedic and vascular teams.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Prof. Venu Kavarthapu from King's College Hospital London led clinical training for Apollo Hospitals India on CERAMENT G deployment. KCL serves as a key opinion leader and training partner for BONESUPPORT's international expansion.

3European Bone & Joint Infection Society (EBJIS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EBJIS collaborated on the SOLARIO study - a multi-centre randomized controlled trial involving 500 patients investigating whether systemic antibiotic duration can be reduced to less than 7 days when combined with local antibiotics. BONESUPPORT co-developed educational content and webinars with EBJIS on bone infection management.

bonesupport.com
Strategic tierMinorTypeOthers
Description

DNB Carnegie Investment Bank AB manages share buyback programs on behalf of BONESUPPORT in accordance with MAR and Safe Harbour Regulation. Makes independent trading decisions regarding timing of acquisitions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global orthopedic and medical device leader with a biologics portfolio (including bone graft substitutes) sold through much larger reconstructive and trauma sales forces; competing at the hospital procurement level across BONESUPPORT's indications.

TypeDirect peer
Description

US-listed orthopedic and neurosurgical medical device company with a meaningful orthobiologics portfolio (e.g., DBM, synthetics) targeting bone regeneration in similar trauma, spine and reconstructive indications to BONESUPPORT.

TypeDirect peer
Description

Spine-focused orthopedics and biologics company with a bone graft substitute portfolio directly comparable in product type and surgical use case to CERAMENT.

TypeBroad incumbent
Description

Spine and orthopedic device company with orthobiologics offerings (including synthetic and DBM bone grafts) used in spine and trauma procedures — overlapping technology and surgical specialties.

TypeOthers
Description

Materials supplier of bioceramic and polymer biomaterials to orthobiologics and medical device manufacturers; adjacent rather than competitive, but comparable in the underlying synthetic bone graft technology space.

TypeBroad incumbent
Description

Largest medtech incumbent with orthopedic and biologics offerings (including spine bone grafts) and global hospital sales coverage — addresses the same trauma, spine and reconstructive indications with broader portfolios.

TypeDirect peer
Description

Pure-play orthobiologics company selling bone graft substitutes and regenerative therapies to orthopedic surgeons — directly comparable product category, customer base (orthopedic surgeons/hospitals), and bone-healing focus.

TypeDirect peer
Description

Spine and orthopedic company selling bone growth stimulators and orthobiologics to the same trauma, spine and reconstructive surgeon customers as BONESUPPORT.

TypeBroad incumbent
Description

Major orthopedic reconstruction and biologics player with bone void fillers and regenerative products used in trauma, joint reconstruction and revision arthroplasty — overlapping indications with CERAMENT.

TypeBroad incumbent
Description

Diversified medical device company with an orthopedics franchise including bone grafts, regenerative technologies and trauma products sold to the same hospital and surgeon customer base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BONESUPPORT

Orthobiologic Bone Graft Substitutesbonesupport.com

BONESUPPORT is a Swedish orthobiologics company that develops and commercializes the CERAMENT injectable bioceramic bone graft substitute platform. It serves hospitals and orthopaedic surgeons globally, with North America representing approximately 75% of revenue and a new India entry via Apollo Hospitals.

What BONESUPPORT does

BONESUPPORT is a Swedish orthobiologics company that develops and commercializes CERAMENT, a proprietary injectable bioceramic bone graft substitute platform, founded in 2000 and headquartered in Lund, Sweden. The company is publicly listed on Nasdaq Stockholm (BONEX) and operates wholly-owned sales subsidiaries across Europe, the United States, and Switzerland, with a distribution partnership covering India. Its products address bone voids and bone infections caused by trauma, infection, disease, or related surgery across use cases including chronic osteomyelitis, fracture-related infection, diabetic foot osteomyelitis, open fractures, periprosthetic joint infection, and benign bone tumors. Hospital customers include Apollo Hospitals, King's College Hospital London, Oxford University Hospital, Manchester University Hospital, Charité Berlin, and HCA Florida Kendall.

The CERAMENT platform is built on a patented biphasic calcium sulphate/hydroxyapatite composition that remodels to host bone in six to twelve months. The product portfolio consists of four SKUs: CERAMENT BONE VOID FILLER (osteoconductive only), CERAMENT G (gentamicin-eluting for broad-spectrum infection coverage), CERAMENT V (vancomycin-eluting for MRSA/MRSE infections), and the CERAMENT Bead Tray accessory for bead delivery. CERAMENT G holds FDA 510(k) clearance as the first and only product indicated to reduce occurrence and recurrence of bone infection in open fractures; CERAMENT V has received FDA Breakthrough Device designation and is currently progressing through the De Novo pathway. Reported clinical outcomes include a 94% infection eradication rate in chronic osteomyelitis (100 patients, 6.05-year average follow-up), 87.5% five-year survival versus 44.9% standard treatment in diabetic foot osteomyelitis, and a 3.7% deep infection rate versus 14.5% standard of care in Gustilo-Anderson IIIB open fractures.

BONESUPPORT generates revenue through direct B2B sales of medical devices to hospitals and orthopaedic surgeons, with field sales teams covering DACH, BeNeLux, UK & Ireland, the Nordics, Iberia, and the United States, supported by KOL-led clinical training programs and a channel partner (Apollo Hospitals) for India. North America represents approximately 75% of total sales, with Europe (EUROW) contributing the balance plus a small initial contribution from India. FY2025 revenue was SEK 1,175 million (up from SEK 899M in 2024 and SEK 591M in 2023), gross margin was 92.6-92.9%, and EBITDA was positive. The company has 101-250 employees and is led by CEO Torbjörn Sköld (effective September 2025) and CFO Håkan Johansson, with Dr. Michael Diefenbeck as Chief Medical Officer. Recent strategic moves include the India launch (May 2026), CMS NTAP approval and proposed improved reimbursement for CERAMENT G in the US, the SOLARIO study readout, and a SEK 100 million share buyback program completed in June 2026.

BONESUPPORT firmographics

Firmographics
Name
BONESUPPORT
Legal name
BONE SUPPORT AB
Website
https://bonesupport.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
BONESUPPORT is a Swedish orthobiologics company that develops and commercializes the CERAMENT injectable bioceramic bone graft substitute platform. It serves hospitals and orthopaedic surgeons globally, with North America representing approximately 75% of revenue and a new India entry via Apollo Hospitals.
Ownership category
akta.pro rank

BONESUPPORT industry classification

Industry
Product category
Orthobiologic Bone Graft Substitutes
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Orthobiologic bone grafts
  • Injectable bioceramic substitutes
  • Drug-eluting bone void filler
  • Antibiotic bone graft substitute
  • Calcium sulphate hydroxyapatite

Where BONESUPPORT is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices10 records

Markets served

BONESUPPORT business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Product Sales: BONESUPPORT generates revenue primarily through the sale of its CERAMENT bone graft substitute products. Products include CERAMENT BONE VOID FILLER (standard), CERAMENT G (gentamicin-eluting), CERAMENT V (vancomycin-eluting), and CERAMENT Bead Tray. Sales are direct to hospitals and healthcare providers through field sales teams.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo public pricing available - B2B medical device sales through hospital procurement

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

BONESUPPORT product offering

Product offering

Core offering

BONESUPPORT develops, manufactures, and commercializes the CERAMENT platform of injectable radiopaque osteoconductive bioceramic bone graft substitutes that remodel to host bone in six to twelve months. The product range includes CERAMENT BONE VOID FILLER for bone void filling, CERAMENT G (gentamicin-eluting) and CERAMENT V (vancomycin-eluting) antibiotic-eluting variants for bone infection management, and the CERAMENT Bead Tray accessory for bead preparation.

Product overview

BONESUPPORT is a Scandinavian orthobiologics company that has developed CERAMENT®, a proprietary technology platform of radiopaque injectable osteoconductive and drug-eluting bioceramic products. The product portfolio consists of four main offerings: CERAMENT® BONE VOID FILLER (core bone void filler without antibiotic), CERAMENT® G (gentamicin-eluting antibiotic bone graft), CERAMENT® V (vancomycin-eluting antibiotic bone graft), and CERAMENT® Bead Tray (accessory for bead delivery). All products remodel to host bone in six to twelve months. The platform enables treatment of bone defects caused by trauma, infection, disease, or related surgery. The antibiotic-eluting products (G and V) combine infection control with bone regeneration in single-stage surgical approaches.

Differentiator

Problem solved

Functional benefit

Brands

  • CERAMENT: Innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products for bone graft substitutes that remodel to host bone in six to twelve months.

Products and services

  • CERAMENT BONE VOID FILLER Radiopaque injectable osteoconductive bioceramic bone graft substitute for filling bone voids and defects, backed by RCT and PROMS data showing bone remodeling outcomes equivalent to autograft. Used for trauma cases at low risk of infection.
  • CERAMENT G Antibiotic-eluting bone graft substitute releasing gentamicin locally. Combines infection control with bone regeneration in single-stage treatment. FDA 510(k) cleared for reducing occurrence and recurrence of bone infection in open fractures. Used for high-risk infection cases, diabetic foot complications, chronic osteomyelitis, and fracture-related infections.
  • CERAMENT V Antibiotic-eluting bone graft substitute releasing vancomycin locally. Designed primarily for bone infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA) or Methicillin-Resistant Staphylococcus epidermidis (MRSE). FDA submission filed for bone infection indication.
  • CERAMENT Bead Tray Optional delivery device accessory for preparing and delivering CERAMENT as pre-hardened beads, particularly useful for bone cysts prone to producing large volumes of fluid such as aneurysmal bone cysts.

Quantifiable outcome

  • 94% infection eradication rate in chronic osteomyelitis (100 patients, avg 6.05 year follow-up)
  • +5 more outcomes

Companies that use BONESUPPORT

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles3 records

BONESUPPORT technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BONESUPPORT partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Apollo HospitalscoreChannel Partner/ Reseller/ Distributor · 7 May 2026Apollo Hospitals introduced CERAMENT G in India as the first advanced antibiotic-eluting bone graft substitute for treating diabetic foot complications and complex bone infections. India has over 89 million people living with diabetes. The partnership includes clinical training programs led by Prof. Venu Kavarthapu from King's College Hospital London to deploy the technology across Apollo's multidisciplinary orthopaedic and vascular teams.
  • King's College Hospital LondoncoreStrategic or Co-development PartnerProf. Venu Kavarthapu from King's College Hospital London led clinical training for Apollo Hospitals India on CERAMENT G deployment. KCL serves as a key opinion leader and training partner for BONESUPPORT's international expansion.
  • European Bone & Joint Infection Society (EBJIS)coreStrategic or Co-development PartnerEBJIS collaborated on the SOLARIO study - a multi-centre randomized controlled trial involving 500 patients investigating whether systemic antibiotic duration can be reduced to less than 7 days when combined with local antibiotics. BONESUPPORT co-developed educational content and webinars with EBJIS on bone infection management.
  • DNB Carnegie Investment Bank ABminorOthersDNB Carnegie Investment Bank AB manages share buyback programs on behalf of BONESUPPORT in accordance with MAR and Safe Harbour Regulation. Makes independent trading decisions regarding timing of acquisitions.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

BONESUPPORT competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Global orthopedic and medical device leader with a biologics portfolio (including bone graft substitutes) sold through much larger reconstructive and trauma sales forces; competing at the hospital procurement level across BONESUPPORT's indications.
  • NuVasive (now Globus Medical): Spine and orthopedic device company with orthobiologics offerings (including synthetic and DBM bone grafts) used in spine and trauma procedures — overlapping technology and surgical specialties.
  • Medtronic: Largest medtech incumbent with orthopedic and biologics offerings (including spine bone grafts) and global hospital sales coverage — addresses the same trauma, spine and reconstructive indications with broader portfolios.
  • Zimmer Biomet: Major orthopedic reconstruction and biologics player with bone void fillers and regenerative products used in trauma, joint reconstruction and revision arthroplasty — overlapping indications with CERAMENT.
  • Smith+Nephew: Diversified medical device company with an orthopedics franchise including bone grafts, regenerative technologies and trauma products sold to the same hospital and surgeon customer base.

Direct peers

  • Integra LifeSciences: US-listed orthopedic and neurosurgical medical device company with a meaningful orthobiologics portfolio (e.g., DBM, synthetics) targeting bone regeneration in similar trauma, spine and reconstructive indications to BONESUPPORT.
  • SeaSpine (now part of SeaSpine Orthopedics): Spine-focused orthopedics and biologics company with a bone graft substitute portfolio directly comparable in product type and surgical use case to CERAMENT.
  • Bioventus: Pure-play orthobiologics company selling bone graft substitutes and regenerative therapies to orthopedic surgeons — directly comparable product category, customer base (orthopedic surgeons/hospitals), and bone-healing focus.
  • Orthofix Medical: Spine and orthopedic company selling bone growth stimulators and orthobiologics to the same trauma, spine and reconstructive surgeon customers as BONESUPPORT.

Others

  • DSM Biomedical (dsm-firmenich): Materials supplier of bioceramic and polymer biomaterials to orthobiologics and medical device manufacturers; adjacent rather than competitive, but comparable in the underlying synthetic bone graft technology space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

BONESUPPORT social profiles

Digital presence

BONESUPPORT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BONESUPPORT leadership team

Management profile

Number of profiles

Profiles12 records

BONESUPPORT subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

BONESUPPORT funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BONESUPPORT M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BONESUPPORT

What does BONESUPPORT do?

BONESUPPORT develops, manufactures, and commercializes the CERAMENT platform of injectable radiopaque osteoconductive bioceramic bone graft substitutes that remodel to host bone in six to twelve months. The product range includes CERAMENT BONE VOID FILLER for bone void filling, CERAMENT G (gentamicin-eluting) and CERAMENT V (vancomycin-eluting) antibiotic-eluting variants for bone infection management, and the CERAMENT Bead Tray accessory for bead preparation.

Is BONESUPPORT a public or private company?

BONESUPPORT is a public company. It is classified as public and is currently operating.

When was BONESUPPORT founded?

BONESUPPORT was founded in 2000. It employs 101 to 250 people.

Where is BONESUPPORT based?

BONESUPPORT is headquartered in Lund, Sweden, in the Europe region.

How does BONESUPPORT make money?

One revenue line is on record: product Sales.

Who are BONESUPPORT's main competitors?

Broad incumbents on record are Stryker, NuVasive (now Globus Medical), Medtronic, Zimmer Biomet and Smith+Nephew. Direct peers are Integra LifeSciences, SeaSpine (now part of SeaSpine Orthopedics), Bioventus and Orthofix Medical. DSM Biomedical (dsm-firmenich) is listed as an others.

Does BONESUPPORT have an API?

No public API is recorded for BONESUPPORT.

What industry is BONESUPPORT in?

BONESUPPORT's product category is Orthobiologic Bone Graft Substitutes. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewBuy-back of ordinary shares in BONESUPPORT HOLDING AB November 9-13, 2026 (week 46)BONESUPPORT repurchased 25,000 ordinary shares between November 9-13, 2026, as part of a SEK 100 million buy-back program. The repurchases totaled SEK 7,979,553, and the program ends no later than February 26, 2027.TradingViewBONESUPPORT HOLDING AB (BONEX) Repurchased 25,000 SharesBONESUPPORT repurchased 25,000 ordinary shares from November 9 through 13, 2026, under its buy-back program capped at SEK 100M. The program runs through February 26, 2027, and treasury shares total 826,820. No repurchase value or cumulative spending was disclosed.Dagens industriBonesupports tidigare vd miljondumpar aktierEmil Billbäck, former CEO of Bonesupport, sold 60,000 shares on Friday at 320.46 SEK each. The sale was reported on 10 November 2026.TradingViewWeekly Edge Case – BonesupportBONESUPPORT's Value score rose from Fairly Priced to Attractively Priced while shares trade near their 52-week high. The orthopaedic medtech's Momentum was already Very Strong, and the divergence is flagged by Market Edge.Dagens industriBonesupport-direktör storsäljer efter kursrusningenBonesupport's Q4 results were received with jubilation on the market, and the stock surged over 24% on the reporting day. A top director sold shares for 6.3 million SEK. The stock continued to rise the next day.Dagens industri”Short squeeze” i rapportvinnarenBonesupport's stock rose 24% on its report, partly due to a short squeeze where short sellers lost money. The rally was explained by the short squeeze, with CEO Torbjörn Sköld named.Seeking AlphaBonesupport Holding AB (publ) (BOEUF) Q3 2026 Earnings Call TranscriptBonesupport Holding reported Q3 2026 net sales of SEK 409 million, up 38% at constant exchange rates versus Q3 2025. Adjusted operating margin was 34%, with operating cash flow reaching SEK 138 million.Investing.comEarnings call transcript: BONESUPPORT jumps on q3 growth, reimbursement boostBONESUPPORT reported Q3 2026 net sales of SEK 409 million, up 39% year-over-year, with adjusted operating margin at 34%. The company cited strong U.S. CERAMENT G sales and a new U.S. reimbursement ruling as key drivers. It kept its full-year 2026 growth guidance of 33-36% in constant currencies.Investing.comEarnings call transcript: BONESUPPORT jumps on q3 growth, reimbursement boostBONESUPPORT reported Q3 2026 net sales of SEK 409 million, up 39% year-over-year, with adjusted operating margin at 34%. The company cited strong U.S. CERAMENT G sales and a new U.S. reimbursement ruling as key drivers, and kept its full-year growth guidance of 33-36% in constant currencies.Dagens industriSelinbolaget rusar tvåsiffrigt efter vinstlyft: ”Väldigt nöjda”Bonesupport, a medical technology company, reported a two-digit stock rally on Thursday after its Q3 2026 results. CEO Torbjörn Sköld said the company is very satisfied with the quarter. The company is owned by Erik Selin, a real estate profile.